Schizophrenia: A review of potential biomarkers.

OBJECTIVES Understanding the biological process and progression of schizophrenia is the first step to developing novel approaches and new interventions. Research on new biomarkers is extremely important when the goal is an early diagnosis (prediction) and precise theranostics. The objective of this review is to understand the research on biomarkers and their effects in schizophrenia to synthesize the role of these new advances. METHODS In this review, we search and review publications in databases in accordance with established limits and specific objectives. We look at particular endpoints such as the category of biomarkers, laboratory techniques and the results/conclusions of the selected publications. RESULTS The investigation of biomarkers and their potential as a predictor, diagnosis instrument and therapeutic orientation, requires an appropriate methodological strategy. In this review, we found different laboratory techniques to identify biomarkers and their function in schizophrenia. CONCLUSION The consolidation of this information will provide a large-scale application network of schizophrenia biomarkers.

[1]  Branka Vidrih,et al.  Increased calcium-independent lipoprotein phospholipase A2 but not protein S100 in patients with schizophrenia. , 2016, Psychiatria Danubina.

[2]  F. Bookstein,et al.  A new statistical method for testing hypotheses of neuropsychological/MRI relationships in schizophrenia: partial least squares analysis , 2002, Schizophrenia Research.

[3]  Jessica A. Turner,et al.  Behavioral Interpretations of Intrinsic Connectivity Networks , 2011, Journal of Cognitive Neuroscience.

[4]  Godfrey D Pearlson,et al.  Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer). , 2015, Schizophrenia bulletin.

[5]  E. Costa,et al.  Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder , 2007, Schizophrenia Research.

[6]  J. Horáček,et al.  Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. , 2012, Psychiatria Danubina.

[7]  Nicholas J Schork,et al.  PhenoChipping of psychotic disorders: A novel approach for deconstructing and quantitating psychiatric phenotypes , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[8]  R. Lenroot,et al.  Peripheral BDNF: a candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia , 2014, Psychological Medicine.

[9]  A. Niculescu.  Polypharmacy in oligopopulations: what psychiatric genetics can teach biological psychiatry , 2006, Psychiatric genetics.

[10]  Lars T. Westlye,et al.  Assessing brain structural associations with working-memory related brain patterns in schizophrenia and healthy controls using linked independent component analysis , 2015, NeuroImage: Clinical.

[11]  N. Craddock,et al.  The genetics of schizophrenia and bipolar disorder: dissecting psychosis , 2005, Journal of Medical Genetics.

[12]  H. Hwu,et al.  Differentiation of Schizophrenia Patients from Healthy Subjects by Mismatch Negativity and Neuropsychological Tests , 2012, PloS one.

[13]  J. Leon.  Is it time to awaken Sleeping Beauty? European psychiatry has been sleeping since 1980. , 2014 .

[14]  N. Schork,et al.  Discovery and validation of blood biomarkers for suicidality , 2013, Molecular Psychiatry.

[15]  Jennifer M. Coughlin,et al.  Inflammatory molecular signature associated with infectious agents in psychosis. , 2014, Schizophrenia bulletin.

[16]  T. Ekström,et al.  Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  A. Bird,et al.  Genomic DNA methylation: the mark and its mediators. , 2006, Trends in biochemical sciences.

[18]  Abdellah Tebani,et al.  Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations , 2016, International journal of molecular sciences.

[19]  M. Vawter,et al.  An integrative functional genomics approach for discovering biomarkers in schizophrenia. , 2011, Briefings in functional genomics.

[20]  Sun-Chong Wang,et al.  High Precision DNA Modification Analysis of HCG9 in Major Psychosis , 2015, Schizophrenia bulletin.

[21]  Eric J. Nestler,et al.  Epigenetic regulation in psychiatric disorders , 2007, Nature Reviews Neuroscience.

[22]  Emanuel Schwarz,et al.  Comparison of Peripheral and Central Schizophrenia Biomarker Profiles , 2012, PloS one.

[23]  M. Keshavan,et al.  White matter diffusivity and microarchitecture among schizophrenia subjects and first-degree relatives , 2015, Schizophrenia Research.

[24]  Matcheri S. Keshavan,et al.  Associations between Purine Metabolites and Clinical Symptoms in Schizophrenia , 2012, PloS one.

[25]  D. V. Vactor,et al.  MicroRNAs Shape the Neuronal Landscape , 2012, Neuron.

[26]  H. Okano,et al.  Utility of Scalp Hair Follicles as a Novel Source of Biomarker Genes for Psychiatric Illnesses , 2015, Biological Psychiatry.

[27]  A. Dwork,et al.  Proteomics Research in Schizophrenia , 2016, Front. Cell. Neurosci..

[28]  S. Sethi,et al.  Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders , 2015, The international journal of neuropsychopharmacology.

[29]  Jingping Zhao,et al.  APOA-I: A Possible Novel Biomarker for Metabolic Side Effects in First Episode Schizophrenia , 2014, PloS one.

[30]  K. Krishnan,et al.  Metabolomic mapping of atypical antipsychotic effects in schizophrenia , 2007, Molecular Psychiatry.

[31]  P. Lio’,et al.  Identification of Targeted Analyte Clusters for Studies of Schizophrenia* , 2009, Molecular & Cellular Proteomics.

[32]  J. Leza,et al.  Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. , 2014, Schizophrenia bulletin.

[33]  M. Su,et al.  Potential metabolite markers of schizophrenia , 2011, Molecular Psychiatry.

[34]  A. Guidotti,et al.  Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation. , 2009, Epigenomics.

[35]  S. Akbarian,et al.  Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders , 2006, Brain Research Reviews.

[36]  Heinz Häfner,et al.  Early detection of schizophrenia: current evidence and future perspectives. , 2006, World psychiatry : official journal of the World Psychiatric Association.

[37]  N. Bargalló,et al.  Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls , 2015, Translational Psychiatry.

[38]  Mingxiong Huang,et al.  Cognitive abilities and 50- and 100-msec paired-click processes in schizophrenia. , 2010, The American journal of psychiatry.

[39]  A. Guidotti,et al.  Toward the Identification of Peripheral Epigenetic Biomarkers of Schizophrenia , 2014, Journal of neurogenetics.

[40]  Rima Kaddurah-Daouk,et al.  Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases , 2009, Neuropsychopharmacology.

[41]  J. Nascimento,et al.  The proteome of schizophrenia , 2015, npj Schizophrenia.

[42]  R. Vasan,et al.  Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations , 2006, Circulation.

[43]  Deanna M Barch,et al.  Stress-System Genes and Life Stress Predict Cortisol Levels and Amygdala and Hippocampal Volumes in Children , 2014, Neuropsychopharmacology.

[44]  E. Petricoin,et al.  Proteomic analysis of eccrine sweat: implications for the discovery of schizophrenia biomarker proteins. , 2012, Journal of proteome research.

[45]  Vince D. Calhoun,et al.  Sparse representation based biomarker selection for schizophrenia with integrated analysis of fMRI and SNPs , 2014, NeuroImage.

[46]  H. Yamasue,et al.  A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study , 2014, Translational Psychiatry.

[47]  A. Gadelha,et al.  Association of biomarkers and depressive symptoms in schizophrenia , 2011, Neuroscience Letters.

[48]  L. Monteggia,et al.  Decoding transcriptional repressor complexes in the adult central nervous system , 2014, Neuropharmacology.

[49]  A. Niculescu,et al.  Convergent Functional Genomics: what we have learned and can learn about genes, pathways, and mechanisms , 2010, Neuropsychopharmacology.

[50]  J. Klosterkötter,et al.  CSF Metabolic and Proteomic Profiles in Patients Prodromal for Psychosis , 2007, PloS one.

[51]  D. Martins‐de‐Souza.  Proteomics tackling schizophrenia as a pathway disorder. , 2012, Schizophrenia bulletin.

[52]  M. Webster,et al.  Schizophrenia and bipolar disorder show both common and distinct changes in cortical interneuron markers , 2014, Schizophrenia Research.

[53]  F. Perera,et al.  DNA methylation of BDNF as a biomarker of early-life adversity , 2014, Proceedings of the National Academy of Sciences.

[54]  T. Schneider-Axmann,et al.  Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[55]  Rima Kaddurah-Daouk,et al.  Metabolomics tools for identifying biomarkers for neuropsychiatric diseases , 2009, Neurobiology of Disease.

[56]  H. Breiter,et al.  Cannabis‐related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects , 2015, Hippocampus.

[57]  M. Bortolomasi,et al.  Altered Gene Expression in Schizophrenia: Findings from Transcriptional Signatures in Fibroblasts and Blood , 2015, PloS one.

[58]  R. Murray,et al.  Pattern of neural responses to verbal fluency shows diagnostic specificity for schizophrenia and bipolar disorder , 2011, BMC psychiatry.

[59]  S. A. Wijtenburg,et al.  Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia , 2015, Neuropsychopharmacology.

[60]  M. Knyazeva,et al.  Glutathione Precursor N-Acetyl-Cysteine Modulates EEG Synchronization in Schizophrenia Patients: A Double-Blind, Randomized, Placebo-Controlled Trial , 2012, PloS one.

[61]  Stephen J Glatt,et al.  Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: Convergent pathway analysis findings from two independent samples , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[62]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[63]  B. Turetsky,et al.  Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. , 2000, Archives of general psychiatry.

[64]  Dewen Hu,et al.  Convergent and Divergent Functional Connectivity Patterns in Schizophrenia and Depression , 2013, PloS one.

[65]  V. Kumari,et al.  Sleep Deprivation Disrupts Prepulse Inhibition and Induces Psychosis-Like Symptoms in Healthy Humans , 2014, The Journal of Neuroscience.

[66]  Anthony J. Rissling,et al.  Automatic sensory information processing abnormalities across the illness course of schizophrenia , 2011, Psychological Medicine.

[67]  R. Freedman,et al.  Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia. , 2014, The American journal of psychiatry.

[68]  M. Tsuang,et al.  Similarities and differences in peripheral blood gene‐expression signatures of individuals with schizophrenia and their first‐degree biological relatives , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[69]  Peter F. Buckley,et al.  Biomarkers in Schizophrenia: A Brief Conceptual Consideration , 2013, Disease markers.

[70]  Marquis P. Vawter,et al.  The first decade and beyond of transcriptional profiling in schizophrenia , 2012, Neurobiology of Disease.

[71]  Noam Shomron,et al.  Molecular Risk Factors for Schizophrenia. , 2016, Trends in molecular medicine.

[72]  K. Iwamoto,et al.  Comprehensive DNA methylation and hydroxymethylation analysis in the human brain and its implication in mental disorders , 2014, Neuropharmacology.

[73]  D. Goff,et al.  Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR) , 2010, Psychiatry Research.

[74]  R. Murray,et al.  Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. , 2011, The Journal of clinical psychiatry.

[75]  A. Niculescu.  Schizophrenia: from genetics to biology to predictive medicine. , 2014, The Journal of clinical psychiatry.

[76]  R. Neubert,et al.  Skin ceramide alterations in first-episode schizophrenia indicate abnormal sphingolipid metabolism. , 2013, Schizophrenia bulletin.

[77]  Gustavo Deco,et al.  Functional connectivity dynamics: Modeling the switching behavior of the resting state , 2015, NeuroImage.

[78]  M. Mintun,et al.  Brain work and brain imaging. , 2006, Annual review of neuroscience.

[79]  E. Bora.  Neurodevelopmental origin of cognitive impairment in schizophrenia , 2014, Psychological Medicine.

[80]  A. Bird,et al.  Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.

[81]  Peter Falkai,et al.  Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. , 2010, Journal of psychiatric research.

[82]  R. Fuller,et al.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. , 2011, Archives of general psychiatry.

[83]  G. Tsangaris,et al.  The audacity of proteomics: a chance to overcome current challenges in schizophrenia research , 2009, Expert review of proteomics.

[84]  Vince D. Calhoun,et al.  Identification of Imaging Biomarkers in Schizophrenia: A Coefficient-constrained Independent Component Analysis of the Mind Multi-site Schizophrenia Study , 2010, Neuroinformatics.

[85]  F. Benes,et al.  Circuit- and Diagnosis-Specific DNA Methylation Changes at γ-Aminobutyric Acid-Related Genes in Postmortem Human Hippocampus in Schizophrenia and Bipolar Disorder. , 2015, JAMA psychiatry.

[86]  G. Pearlson,et al.  Mediodorsal and visual thalamic connectivity differ in schizophrenia and bipolar disorder with and without psychosis history. , 2014, Schizophrenia bulletin.

[87]  J. Suvisaari,et al.  Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. , 2007, The Journal of clinical psychiatry.

[88]  A. Guidotti,et al.  Reelin promoter hypermethylation in schizophrenia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[89]  J. Lauriello,et al.  Glutamate as a Marker of Cognitive Function in Schizophrenia: A Proton Spectroscopic Imaging Study at 4 Tesla , 2011, Biological Psychiatry.

[90]  R. Goodacre,et al.  The role of metabolites and metabolomics in clinically applicable biomarkers of disease , 2010, Archives of Toxicology.

[91]  Michael F. Green,et al.  Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2 , 2015, Schizophrenia Research.

[92]  Yuqin Wang,et al.  Targeted metabolomics for biomarker discovery. , 2010, Angewandte Chemie.

[93]  Nishant Goyal,et al.  Evaluation of resting state gamma power as a response marker in schizophrenia , 2015, Psychiatry and clinical neurosciences.

[94]  E. Walker,et al.  An examination of associations between the inability to taste phenylthiocarbamide (PTC) and clinical characteristics and trait markers in first-episode, nonaffective psychotic disorders , 2013, Psychiatry Research.

[95]  P. McKenna,et al.  High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. , 2008, Journal of proteome research.

[96]  Young-Chul Chung,et al.  The mRNA Expression Status of Dopamine Receptor D2, Dopamine Receptor D3 and DARPP-32 in T Lymphocytes of Patients with Early Psychosis , 2015, International journal of molecular sciences.

[97]  E. Stein,et al.  Smoking and Schizophrenia Independently and Additively Reduce White Matter Integrity Between Striatum and Frontal Cortex , 2010, Biological Psychiatry.

[98]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[99]  R. Yolken,et al.  Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset , 2015, Translational Psychiatry.

[100]  Erika P. Raven,et al.  Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory , 2011, Schizophrenia Research.

[101]  S. Rozen,et al.  Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia , 2010, Molecular Psychiatry.

[102]  M. Raichle,et al.  Searching for a baseline: Functional imaging and the resting human brain , 2001, Nature Reviews Neuroscience.

[103]  P. Kochunov,et al.  Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. , 2014, JAMA psychiatry.

[104]  V. Janout,et al.  Epidemiology and risk factors of schizophrenia. , 2016, Neuro endocrinology letters.

[105]  F Baganz,et al.  Systematic functional analysis of the yeast genome. , 1998, Trends in biotechnology.

[106]  F. Kapczinski,et al.  Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. , 2011, Revista brasileira de psiquiatria.

[107]  A. Guidotti,et al.  Epigenetic RELN Dysfunction in Schizophrenia and Related Neuropsychiatric Disorders , 2016, Front. Cell. Neurosci..

[108]  A. Fischer.  Epigenetic memory: the Lamarckian brain , 2014, The EMBO journal.

[109]  S. Akbarian.  Epigenetic mechanisms in schizophrenia , 2014, Dialogues in clinical neuroscience.

[110]  C. Allis,et al.  The molecular hallmarks of epigenetic control , 2016, Nature Reviews Genetics.

[111]  Dongdong Lin,et al.  Integrating fMRI and SNP data for biomarker identification for schizophrenia with a sparse representation based variable selection method , 2013, BMC Medical Genomics.

[112]  Scott R Sponheim,et al.  Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls. , 2012, Schizophrenia bulletin.

[113]  J. Vincent,et al.  A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder , 2012, Molecular Psychiatry.

[114]  Thomas J. Whitford,et al.  Investigating the neuropsychological and neuroanatomical changes that occur over the first 2–3 years of illness in patients with first-episode schizophrenia , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[115]  D. Rujescu,et al.  Schizophrenia shows a unique metabolomics signature in plasma , 2012, Translational Psychiatry.

[116]  H. Lockstone,et al.  Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia. , 2010, Journal of proteome research.

[117]  S. Akbarian,et al.  Thomas Vicary and the Anatomie of Mans Body , 2006, Medical History.

[118]  V. Calhoun,et al.  MB-COMT promoter DNA methylation is associated with working-memory processing in schizophrenia patients and healthy controls , 2014, Epigenetics.

[119]  A. Guidotti,et al.  Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[120]  S. Zorn,et al.  Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment. , 2016, Pharmacology & therapeutics.

[121]  D. Rujescu,et al.  The promise of biological markers for treatment response in first-episode psychosis: a systematic review. , 2015, Schizophrenia bulletin.

[122]  E. Marcotte,et al.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses , 2012, Nature Reviews Genetics.

[123]  Christos Davatzikos,et al.  Accelerated brain aging in schizophrenia and beyond: a neuroanatomical marker of psychiatric disorders. , 2014, Schizophrenia bulletin.

[124]  D. Hochstrasser,et al.  Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. , 1996, Biotechnology & genetic engineering reviews.

[125]  I. Gottesman,et al.  Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. , 2000, American journal of medical genetics.

[126]  S. Potkin,et al.  Biomarkers for drug development in early psychosis: Current issues and promising directions , 2016, European Neuropsychopharmacology.

[127]  K. Kasai,et al.  DNA methylation of the BDNF gene and its relevance to psychiatric disorders , 2013, Journal of Human Genetics.

[128]  S. Faraone,et al.  Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: A preliminary report , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[129]  E. Nestler,et al.  Epigenetic Basis of Mental Illness , 2016, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[130]  Larry J. Seidman,et al.  Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia , 1994, Biological Psychiatry.

[131]  P. Buckley,et al.  Neuroimaging of schizophrenia: structural abnormalities and pathophysiological implications , 2005, Neuropsychiatric disease and treatment.

[132]  M. Bellani,et al.  Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia , 2014, Translational Psychiatry.

[133]  Chi-Yu Lai,et al.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics. , 2016, World journal of psychiatry.

[134]  Paola Dazzan,et al.  Neuroimaging biomarkers to predict treatment response in schizophrenia: the end of 30 years of solitude? , 2014, Dialogues in clinical neuroscience.

[135]  J. Lieberman,et al.  Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1 , 2008, Schizophrenia Research.

[136]  Alain Malafosse,et al.  Increased DNA methylation status of the serotonin receptor 5HTR1A gene promoter in schizophrenia and bipolar disorder. , 2011, Journal of affective disorders.

[137]  J. Nascimento,et al.  Proteomics and molecular tools for unveiling missing links in the biochemical understanding of schizophrenia , 2016, Proteomics. Clinical applications.

[138]  Lifeng Wang,et al.  Identify schizophrenia using resting-state functional connectivity: an exploratory research and analysis , 2012, Biomedical engineering online.

[139]  Kazuo Yamada,et al.  DNA Methylation Status of SOX10 Correlates with Its Downregulation and Oligodendrocyte Dysfunction in Schizophrenia , 2005, The Journal of Neuroscience.

[140]  H. Arai,et al.  Significance of measurements of peripheral carbonyl stress markers in a cross-sectional and longitudinal study in patients with acute-stage schizophrenia. , 2014, Schizophrenia bulletin.

[141]  Martina Wengenroth,et al.  2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. , 2007, Journal of proteome research.

[142]  Elaine Holmes,et al.  Metabolic Profiling of CSF: Evidence That Early Intervention May Impact on Disease Progression and Outcome in Schizophrenia , 2006, PLoS medicine.

[143]  D. Goff,et al.  Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. , 2013, JAMA psychiatry.

[144]  A. Winslow,et al.  Differential Expression of Exosomal microRNAs in Prefrontal Cortices of Schizophrenia and Bipolar Disorder Patients , 2013, PloS one.

[145]  A. Guidotti,et al.  DNA methylation and demethylation as targets for antipsychotic therapy , 2014, Dialogues in clinical neuroscience.

[146]  En,et al.  ¿Es hora de despertar a la Bella Durmiente? En 1980, la psiquiatría europea cayó en un profundo sueño , 2014 .

[147]  E. Severance,et al.  Complement C1q formation of immune complexes with milk caseins and wheat glutens in schizophrenia , 2012, Neurobiology of Disease.

[148]  A. Malhotra,et al.  Coding and Noncoding Gene Expression Biomarkers in Mood Disorders and Schizophrenia , 2013, Disease markers.

[149]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[150]  Jonathan P Roiser,et al.  Cognitive heterogeneity in schizophrenia , 2007, Current opinion in psychiatry.

[151]  Michael D. Spain,et al.  Identification of a biological signature for schizophrenia in serum , 2012, Molecular Psychiatry.

[152]  H. Breiter,et al.  Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects. , 2014, Schizophrenia bulletin.

[153]  T. Sharma,et al.  Neuropsychological function–brain structure relationships and stage of illness: An investigation into chronic and first-episode schizophrenia , 2008, Psychiatry Research: Neuroimaging.

[154]  Eric S. Lander,et al.  A polygenic burden of rare disruptive mutations in schizophrenia , 2014, Nature.